Your browser does not support JavaScript! For Providers | Biofidelity

Make faster, more informed treatment decisions.

A cancer patient exits a healthcare facility.

Every patient deserves the best treatment.

More than 200 targeted therapies are now approved for qualifying cancer patients.1 But fewer than 50% of lung cancer patients receive complete biomarker testing based on the current guidelines for non-small cell lung cancer (NSCLC).2

Existing tests take weeks to deliver results. Many samples fail, requiring repeat biopsies and additional delays. And the process can cost thousands of dollars.

Aspyre Clinical Test for Lung helps you make it possible.

The first application of the Aspyre technology, Aspyre Clinical Test for Lung enables fast, actionable treatment decisions for NSCLC patients.

Aspyre Clinical Test for Lung tests all guideline-recommended genes associated with targeted therapies for NSCLC.

An oncologist shows his patient treatment options.

Aspyre Clinical Test for Lung enables fast, confident treatment decisions.

Aspyre Clinical Test for Lung simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify DNA mutations and RNA fusions, while avoiding the additional time and expense of running separate assays.

Order a Test
Simple

One assay to test all NCCN guideline-recommended genes associated with FDA-approved targeted therapies.

Fast

98% of cases processed within 2 days, meaning patients can go from diagnosis to actionable biomarker results in a matter of days, not weeks.

Reliable

In a recent study, Aspyre demonstrated that 98% of samples that fail NGS are rescued by Aspyre.

Analyzes DNA & RNA

Simultaneously analyzes DNA variants and RNA fusions in a single assay, maximizing the opportunity to identify mutations and fusions.

Coverage of 114 variants across 11 genes, including DNA and RNA biomarkers

Next-day results in a simple, 2-page report.

An example of Aspyre Clinical Test's two-page report.

Aspyre Clinical Test for Lung

The first clinical application of the Aspyre technology, Aspyre Clinical Test for Lung provides fast, actionable biomarker data for non-small cell lung cancer (NSCLC) patients.

Learn More

References

1. Yabroff KR, Zhao J, de Moor JS, Sineshaw HM, Freedman AN, Zheng Z, Han X, Rai A, Klabunde CN. Factors Associated With Oncologist Discussions of the Costs of Genomic Testing and Related Treatments. J Natl Cancer Inst. 2020 May 1;112(5):498-506. doi: 10.1093/jnci/djz173. PMID: 31675070; PMCID: PMC7225678.

2. Sadik H, Pritchard D, Keeling D-M, et al: Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer [Internet]. JCO Precis Oncol 6:e2200246, 2022 Available from: https://ascopubs.org/doi/full/10.1200/PO.22.00246